Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
17 November 2015 - 8:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
|
NOTIFICATION OF LATE FILING |
SEC FILE NUMBER
333-68008 |
|
|
|
|
|
CUSIP NUMBER
[________] |
| (Check
One): | ¨ Form
10-K ¨ Form 20-F ¨ Form
11-K x Form 10-Q ¨ Form
10D |
¨ Form
N-SAR ¨ Form N-CSR
For Period Ended: September 30, 2015
¨ Transition Report on Form 10-K
¨ Transition Report on Form 20-F
¨ Transition Report on Form 11-K
¨ Transition Report on Form 10-Q
¨ Transition Report on Form N-SAR
For the Transition Period Ended: ________________________________________
Read attached instruction sheet before
preparing form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: |
|
PART I - REGISTRANT INFORMATION
Full Name of Registrant |
Skystar Bio-Pharmaceutical Company |
Former Name if Applicable |
|
Address of Principal Executive Office (Street and Number) |
4/F Building B Chuangye Square, No. 48 Keji Road
|
City, State and Zip Code
Gaoxin District, Xi’an, Shaanxi Province,
P.R. China |
|
PART
II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
¨ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or From N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K,
20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time
period.
The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015 (the “Quarterly
Report”) cannot be filed within the prescribed time period because the Registrant requires additional time to complete the
audit of its 2014 financial statements and filing of its Annual Report on Form 10-K for the period ended December 31, 2014 (the
“Annual Report”). The delay in completing the financial statements and Annual Report, in turn, caused the Registrant’s
delay in completing the work necessary to prepare the Quarterly Report, which currently cannot be completed without unreasonable
effort or expense. The Registrant is working to complete the Annual Report as expeditiously as possible.
PART IV
OTHER INFORMATION
(1) |
Name and telephone number of person to contact in regard to this notification |
|
|
|
|
|
|
|
|
Scott
Cramer |
|
(407) |
|
645-4433 |
|
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) |
Have all other periodic reports required under Section
13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify
report(s). |
| · | Annual
Report on Form 10-K for the period ended December 31, 2014. |
¨ Yes x No
| · | Quarterly Reports on Form 10-Q for the periods ended
March 31, 2015 and June 30, 2015. |
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject report or portion thereof? |
x Yes ¨ No
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
|
|
|
Since
2014, the Registrant extended payment terms to its distributors that are responsible for collecting payments from the Registrant’s
customers. As a result, the Registrant expects that its accounts receivable will increase by approximately $16 million and unrestricted
cash will decrease by approximately $14 million as of September 30, 2015 as compared to the same period of the last fiscal year. Because
of slowing market demand, the Registrant expects that its sales for the three months ended September 30, 2015 will decrease by
$11 million as compared to the same period of the last fiscal year. |
Skystar Bio-Pharmaceutical
Company
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date
: November 16, 2015 |
By: |
/s/ Weibing Lu |
|
|
Name: Weibing Lu |
|
|
Title: Chief Executive Officer |
INSTRUCTION: The form may be signed by
an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing
the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant
shall be filed with the form.
|
ATTENTION |
|
|
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |